Victorian Clinical Genetics Services (VCGS)
Abisha Srikumar is a skilled Medical Laboratory Scientist currently working at Victorian Clinical Genetics Services (VCGS) since October 2021, with prior experience in various roles within VCGS, including Laboratory Technician. Abisha has a strong background in healthcare, demonstrated through work at WOLPER JEWISH HOSPITAL, where responsibilities included ensuring efficient operation in the rehabilitation ward. Additionally, experience at the Hawkesbury Institute for the Environment involved analysis of eucalyptus leaf chemistry, contributing to ecological research. Educational credentials include a Master's degree in Clinical Laboratory Science from RMIT University and a Bachelor of Science in Forensic Science from Western Sydney University. Other roles include volunteer teaching and positions in sales and fundraising.
This person is not in any offices
Victorian Clinical Genetics Services (VCGS)
Victorian Clinical Genetics Services (VCGS) is a specialist prenatal, childhood and adult genetics service. We are an Australian not-for-profit subsidiary of Murdoch Children’s Research Institute (MCRI) and one of the largest contributors driving genetic healthcare, research and policy in the country. We marked our 34th anniversary in July 2022 and acknowledge our fantastic donors, funders, supporters and collaborators over this time, including the global genetics community, and the Australian Federal and Victorian State governments. Located on site at The Royal Children’s Hospital (RCH) Melbourne, we provide an integrated genetic consultation, counselling, testing and diagnostic service for children, adults, families, and prospective parents. Our unique service includes the ability to draw on specific expert knowledge from Melbourne Children’s campus partners RCH and The University of Melbourne, providing individuals and families with accessible and high quality healthcare. As a pioneering not-for-profit organisation, all our proceeds go back into translational medical research so that we can continue to develop innovative solutions to complex genetic health challenges.